Literature DB >> 2438302

Monoclonal antibodies to gp110 and gp41 of human immunodeficiency virus.

L H Gosting, J McClure, E S Dickinson, S M Watanabe, K Shriver, L C Goldstein.   

Abstract

Six mouse hybridomas secreting monoclonal antibodies specific for the glycoproteins of human immunodeficiency virus were developed. All six antibodies reacted by radioimmunoprecipitation with the glycoprotein precursor of 150,000 daltons as well as one of the proteolytic processing products of 110,000 daltons (gp110) or 41,000 daltons (gp41). Recombinant polypeptides spanning the env coding region were used to locate epitopes on the glycoprotein molecule. The panel of antibodies detected two distinct epitopes of gp41 and one epitope of gp110. We used the antibodies in indirect immunofluorescence assays to evaluate 13 clinical isolates of human immunodeficiency virus from diverse geographic regions, and we found that the gp110 epitope was recognized on all tested isolates, whereas the two gp41 epitopes were detected on 10 of 13 and 4 of 13 isolates.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438302      PMCID: PMC266101          DOI: 10.1128/jcm.25.5.845-848.1987

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Immunofluorescence on avian sarcoma virus-transformed cells: localization of the src gene product.

Authors:  L R Rohrschneider
Journal:  Cell       Date:  1979-01       Impact factor: 41.582

3.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

Authors:  M G Sarngadharan; M Popovic; L Bruch; J Schüpbach; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

4.  Monoclonal antibodies to cytomegalovirus: rapid identification of clinical isolates and preliminary use in diagnosis of cytomegalovirus pneumonia.

Authors:  L C Goldstein; J McDougall; R Hackman; J D Meyers; E D Thomas; R C Nowinski
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

5.  Only site-directed antibodies reactive with the highly conserved src-homologous region of the v-abl protein neutralize kinase activity.

Authors:  J B Konopka; R L Davis; S M Watanabe; A S Ponticelli; L Schiff-Maker; N Rosenberg; O N Witte
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

6.  Analysis of adenovirus transforming proteins from early regions 1A and 1B with antisera to inducible fusion antigens produced in Escherichia coli.

Authors:  K R Spindler; D S Rosser; A J Berk
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

7.  HTLV-III in symptom-free seronegative persons.

Authors:  S Z Salahuddin; J E Groopman; P D Markham; M G Sarngadharan; R R Redfield; M F McLane; M Essex; A Sliski; R C Gallo
Journal:  Lancet       Date:  1984-12-22       Impact factor: 79.321

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

View more
  7 in total

1.  Characterization of monoclonal antibodies identifying type and strain-specific epitopes of human immunodeficiency virus type 1.

Authors:  V Robert; M Resnicoff; J C Chermann; C Devaux
Journal:  Mol Cell Biochem       Date:  1991-04-10       Impact factor: 3.396

2.  Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system.

Authors:  O Haffar; J Garrigues; B Travis; P Moran; J Zarling; S L Hu
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

3.  B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.

Authors:  R D Schrier; J W Gnann; A J Langlois; K Shriver; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

4.  Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

Authors:  S H Pincus; K G Messer; D H Schwartz; G K Lewis; B S Graham; W A Blattner; G Fisher
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

5.  Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1.

Authors:  J E Merrill; Y Koyanagi; J Zack; L Thomas; F Martin; I S Chen
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

6.  Transmembrane envelope glycoproteins of human immunodeficiency virus type 2 and simian immunodeficiency virus SIV-mac exist as homodimers.

Authors:  M A Rey; A G Laurent; J McClure; B Krust; L Montagnier; A G Hovanessian
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

7.  Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1.

Authors:  P S Linsley; J A Ledbetter; E Kinney-Thomas; S L Hu
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.